TRANSPLANT INTERNATIONAL is a premier open-access journal in the field of transplantation, published by Frontiers Media SA since 1988. With its dedicated scope encompassing the latest research and advancements in organ transplantation and related fields, this journal serves as an essential resource for researchers, clinicians, and healthcare professionals engaged in transplantation medicine. Boasting an impressive 2023 Scopus rank of #17 out of 54 in the Medicine - Transplantation category and a Q2 quartile ranking, it has established itself as a vital publication platform contributing to the global discourse on transplant innovations. As an open-access journal since 2022, TRANSPLANT INTERNATIONAL enhances the dissemination of knowledge, ensuring that pivotal findings are accessible to a broader audience, thereby fostering advancements in patient care and clinical practices. With its base in Italy and operations managed from Lausanne, Switzerland, the journal promises to remain at the forefront of transplantation research through 2024 and beyond.

Transplantation Direct is a leading open access journal in the field of transplantation, published by the prestigious Lippincott Williams & Wilkins. Since its inception in 2015, the journal has provided a vital platform for the dissemination of high-quality research and advancements related to organ transplantation. With an impact factor that places it in the Q2 category among transplantation journals, it ranks #22 out of 54 in the Medicine - Transplantation Scopus classification, reflecting its significance and authority within the discipline. The journal not only covers a broad scope of topics related to transplantation but also encourages global collaboration and knowledge exchange amongst researchers, clinicians, and students. With its open access model, Transplantation Direct ensures that groundbreaking findings are accessible to a wider audience, fostering innovation and enhancing patient care worldwide. For more information, visit their address at TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103.

HLA, published by WILEY, is a distinguished academic journal that serves as a vital resource in the fields of Immunology, Genetics, and Allergy. With an ISSN of 2059-2302 and an E-ISSN of 2059-2310, HLA aims to provide cutting-edge research and developments that expand our understanding of human immunology, particularly concerning histocompatibility and antigen systems. Although it currently holds a Q4 quartile ranking in several categories—including Genetics and Immunology—it offers a platform for innovative studies that can catalyze new insights within the scientific community. The journal operates on an Open Access model, ensuring broader accessibility and engagement with emerging discoveries. Researchers, healthcare professionals, and students alike are encouraged to contribute to and utilize this journal to foster advancements in this rapidly evolving field. For submissions and more information, authors can navigate directly to its online portal, embracing the ongoing discourse in immunological research.

OncoImmunology is a leading peer-reviewed journal published by Taylor & Francis Inc, dedicated to advancing the understanding of the dynamic interplay between the immune system and cancer. Established in 2012 and adopting an open access model since 2020, OncoImmunology provides a platform for high-quality research disseminated globally, with a notable focus on innovative therapies and immunotherapeutic strategies aimed at improving patient outcomes. The journal boasts an impressive impact in the field, holding Q1 rankings in both Immunology and Oncology categories for 2023, and it is recognized within the top-tier journals in its domain, reflected in its Scopus ranks and percentiles. With contributions from leading experts and a wide audience of researchers, clinicians, and advanced students, OncoImmunology not only facilitates scholarly dialogue but also addresses pivotal challenges in cancer treatment, making it an essential resource for those invested in the future of oncological and immunological research.

JOURNAL OF EXPERIMENTAL MEDICINE, published by Rockefeller University Press, is a renowned peer-reviewed journal dedicated to advancing the field of experimental medicine since its inception in 1896. With an impressive impact factor and categorized in the Q1 quartile for Immunology, Immunology and Allergy, and Miscellaneous Medicine, this journal stands at the forefront of medical research and innovation. It provides a prestigious platform for scholars and practitioners to disseminate groundbreaking findings that drive the understanding of disease mechanisms and therapeutic strategies. While the journal is not open access, it maintains high visibility and engagement within the scientific community, fostering collaboration among researchers, professionals, and students alike. The journal's consistent ranking in the top percentiles of Scopus illustrates its significant impact and commitment to excellence in medical research.

Current Opinion in Organ Transplantation, published by Lippincott Williams & Wilkins, serves as a leading journal in the fields of immunology and transplantation, providing insightful reviews and expert opinions that shape the discourse in these vital areas of medical research. With an impact factor showcasing its significance and influence in the academic community, this journal is ranked in the Q2 category for both Immunology and Transplantation according to the 2023 metrics, affirming its essential role in advancing knowledge and understanding. Spanning from its inception in 2001 through to 2024, Current Opinion in Organ Transplantation offers a platform for researchers, professionals, and students to engage with the latest advancements and trends, contributing to the ongoing dialogue that drives innovation in organ transplantation and immunological therapies. Although the journal does not currently offer open access options, its rigorous peer-review process and reputable publisher ensure the highest quality of research dissemination, making it an invaluable resource for those invested in the future of organ transplantation.

Annals of Transplantation is a renowned academic journal published by INT SCIENTIFIC INFORMATION, INC, dedicated to the field of transplantation medicine. With a strong historical presence since its inception in 1996, this journal continues to provide a vital platform for disseminating innovative research, clinical studies, and review articles that contribute significantly to the ever-evolving landscape of organ transplantation. Holding a respectable Q2 ranking in the field of transplantation and a Q3 ranking in broader medicine categories as of 2023, the journal stands out with an impactful repository of knowledge that caters to a diverse audience, including researchers, healthcare professionals, and students. While it currently does not operate under an open access model, the scholarly contributions within are crucial for advancing practices, policies, and outcomes in transplantation. Whether you are seeking to keep abreast of recent advances or looking to publish your own findings, Annals of Transplantation serves as an essential resource for fostering collaboration and innovation in medical science.

Science Immunology, published by the American Association for the Advancement of Science, is a leading journal in the field of immunology, recognized for its significant impact and rigor in advancing our understanding of immune responses and complex diseases. With an impressive impact factor that places it in the Q1 category of both immunology and allergy, as well as miscellaneous medicine, this journal is ranked #7 and #8 in their respective Scopus categories, reflecting its high-quality research output. Since its inception in 2016, Science Immunology has been at the forefront of interdisciplinary immunological research, fostering crucial insights that link immunology with pressing health challenges. The journal is committed to providing open access to its content, ensuring that groundbreaking findings are accessible to a global audience of researchers, professionals, and students. Its anthology not only addresses fundamental immunological mechanisms but also enhances the dialogue on translational applications and therapeutic interventions, solidifying its position as an essential resource within the scientific community.

ImmunoTargets and Therapy is a leading open access journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the field of immunology and its various therapeutic applications. Since its inception in 2012, the journal has rapidly become a vital resource for researchers, professionals, and students, achieving notable recognition with a Q1 ranking in both Immunology and Immunology and Allergy categories as of 2023. With an impressive Scopus ranking of #22 out of 233 in Medicine - Immunology and Allergy, and #25 out of 236 in Immunology and Microbiology, this journal maintains a 90th percentile standing in its field. ImmunoTargets and Therapy not only publishes original research articles, reviews, and clinical studies, but also fosters an inclusive platform for the dissemination of innovative findings critical to the fight against immunological disorders. Based in New Zealand, it serves a global audience, promoting knowledge exchange and collaboration through its open access model.

Cancer Immunology Immunotherapy, published by Springer, stands as a premier journal in the fields of cancer research and immunology, holding a prestigious Q1 ranking across multiple categories, including Oncology and Medicine as of 2023. With an ISSN of 0340-7004 and an E-ISSN of 1432-0851, this journal has been a pivotal platform for groundbreaking research since its inception in 1976, continuing to provide insight into the complex interactions between the immune system and cancer. The journal's scope encompasses a wide array of topics, including novel therapeutic strategies, immunological mechanisms, and translational science aimed at advancing treatment outcomes for cancer patients. Renowned for its rigorous peer-review process and high impact factor, it attracts contributions from leading experts and researchers around the globe, positioning itself among the top-tier publications with Scopus rankings that reflect its vital role in advancing the field. Access options are generally subscription-based, ensuring a comprehensive resource for professionals and academics seeking to deepen their understanding and make meaningful contributions to cancer immunotherapy.